WEST LAFAYETTE, Ind. – Kylin Therapeutics Inc., a developer of next-generation RNAi therapeutics, announced that Heartland Angels of Skokie, Ill., has participated in Kylin’s Series A-1 offering. Heartland joins Golden Pine Ventures of Durham, N.C., in this round of financing. “The environment for biotech start-ups in Indiana is excellent, and investors from outside the state are recognizing this,” said Eric Davis, Kylin’s president and CEO.

About Kylin Therapeutics Inc.

Kylin Therapeutics Inc. is a biotechnology company focused on the development of a novel platform technology called pRNA. pRNA is a discrete, RNA-based nanoparticle system. Kylin has re-engineered pRNA to induce RNA interference (RNAi). The resulting therapeutic platform is called pRNAi. This platform represents the next generation of RNAi-inducing therapeutics with superior pharmacokinetics and potency over siRNA.

President and CEO Eric Davis may be contacted at (765) 269-8030 or by email at edavis@kylintherapeutics.com. More information regarding Kylin Therapeutics may be found at www.kylintherapeutics.com.